Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perphenazine added to Matrix Therapy for methamphetamine dependence
IRCT20090801002266N13Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of Perphenazine in methamphetamine use disorder (MUD) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Assessment of craving for methamphetamine and Return to methamphetamine use. Started Nov 2019; status: completed.
02
Drugs
Perphenazine
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on IRCT20090801002266N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N13.